WEAV Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Weave Communications to Francisco Partners

MONSEY, N.Y., Sept. 15, 2026 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Weave Communications, Inc. (NYSE: WEAV) (“Weave”) to Francisco Partners, pursuant to which Weave shareholders will receive $7.40 per share in cash.

Notably, the $7.40 sale price is below Weave’s 52-week high of $7.98, which potentially indicates an opportunistic purchase below fair value.

In addition, the sale price is below the price targets of multiple Wall Street analysts covering Weave before the sale was announced, including:

• Tyler Radke of Citi ($9.00 price target)
• Alexander Sklar of Raymond James ($9.00 price target)
• Josh Nichols of B. Riley Securities ($8.25 price target)
• Mark Schappel of Loop Capital Markets ($8.00 price target)

(Source: TipRanks)

If you remain a Weave shareholder and have concerns about the fairness of the proposed sale, you may contact our firm at the following link to discuss your legal rights at no charge:

https://wohlfruchter.com/cases/weave/

Alternatively, you may contact us by phone at 866-833-6245, or via email at [email protected].

“We are investigating whether the Weave Board of Directors acted in the best interests of Weave shareholders in approving the sale,” explained Joshua Fruchter, a founding partner of Wohl & Fruchter. “This includes whether the cash consideration agreed upon is fair to Weave shareholders considering the stock’s recent trading history, and whether all material information regarding the transaction has been fully disclosed. We encourage Weave stockholders to contact us if they have any concerns.”

About Wohl & Fruchter
Wohl & Fruchter LLP has for over a decade been representing investors in litigation arising from fraud and other corporate misconduct, and has recovered hundreds of millions of dollars in damages for investors. Please visit our website, www.wohlfruchter.com, to learn more about our Firm, or contact one of our partners.

Contact:
Wohl & Fruchter LLP
Joshua E. Fruchter
Toll Free 866.833.6245
[email protected]
www.wohlfruchter.com

You May Also Be Interested In

• NeuroOne Secures First Pharmaceutical Industry Purchase Order for StereoCED™ Drug Delivery Platform to Support Tier 1 Global Pharmaceutical Company's Research Program
• Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB
• ECGI Holdings Inc. (OTC: ECGI) Gains Entry into Coordinated Care Through Avanta Group Acquisition